Literature DB >> 18273730

Curative ablation for atrial fibrillation: a systematic review.

Knut Gjesdal1, Gunn E Vist, Einar Bugge, Ole Rossvoll, Marit Johansen, Inger Norderhaug, Ole-J Ohm.   

Abstract

OBJECTIVE: To perform a systematic review of randomized controlled trials (RCTs) on catheter ablation for atrial fibrillation (AF).
BACKGROUND: Radiofrequency catheter (RF)-ablation around pulmonary vein ostia and in left atrium may reduce or prevent recurrence of AF, as documented in observational studies and registry reports; however, few RCTs are available.
METHODS: Using relevant search phrases, Cochrane Library, MEDLINE and EMBASE were searched for RCTs, last time in May 2007. Titles and abstracts were screened. When entry criteria were fulfilled, full-text papers were read and graded according to quality and relevance.
RESULTS: One thousand and ninety four abstracts were evaluated, and five RCTs included (578 randomized patients). The studies had moderate quality and relevance, but the results were consistent: ablation is better than drug treatment in preventing AF recurrence; the relative risk (95% CI)) one year after ablation ranged from 0.20 (0.08-0.51) to 0.62 (0.39-0.99).
CONCLUSIONS: Results from observational and registry studies are confirmed: RF-ablation reduces recurrence rate of AF, and can be done with few serious complications. Limitations are few patients>70 years, and only one year follow-up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18273730     DOI: 10.1080/14017430701798838

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  4 in total

1.  Efficacy of adjunctive ablation of complex fractionated atrial electrograms and pulmonary vein isolation for the treatment of atrial fibrillation: a meta-analysis of randomized controlled trials.

Authors:  Melissa H Kong; Jonathan P Piccini; Tristram D Bahnson
Journal:  Europace       Date:  2010-10-30       Impact factor: 5.214

Review 2.  Catheter ablation versus anti-arrhythmic drug therapy for the management of a trial fibrillation: a meta-analysis.

Authors:  Xiaofeng Cheng; Xiaoqing Li; Yun He; Xiaoyan Liu; Guoqiang Wang; Li Cheng; Jianbo Hu
Journal:  J Interv Card Electrophysiol       Date:  2014-12-04       Impact factor: 1.900

3.  Is an elevated burden of antiarrhythmic drug (AAD) side-effects the unavoidable price to be traded for a durable suppression of AF relapses in ablated patients? The weaknesses and risks of the AAD suppression algorithm used by current models of AF secondary prevention after catheter ablation.

Authors:  Renato De Vecchis
Journal:  Eur J Clin Pharmacol       Date:  2019-01-29       Impact factor: 2.953

4.  Case report: paravalvular leak as a complication of percutaneous catheter ablation for atrial fibrillation.

Authors:  Orcun Gurbuz; Abdulkadir Ercan; Hakan Ozkan; Gencehan Kumtepe; Ilker H Karal; Serdar Ener
Journal:  J Cardiothorac Surg       Date:  2014-12-17       Impact factor: 1.637

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.